KYOWA KIRIN CO., LTD.
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1949-07-01
- Employees
- 5.9K
- Market Cap
- -
- Website
- http://www.kyowa-kirin.co.jp
Clinical Trials
234
Trial Phases
5 Phases
Drug Approvals
16
Drug Approvals
Cinacalcet Hydrochloride Tablets
- Product Name
- 盖平
- Approval Number
- 国药准字HJ20140508
- Approval Date
- Mar 18, 2024
Cinacalcet Hydrochloride Tablets
- Product Name
- 盖平
- Approval Number
- 国药准字HJ20140509
- Approval Date
- Mar 18, 2024
Human Erythropoietin Injection
- Product Name
- 利血宝
- Approval Number
- 国药准字SJ20171018
- Approval Date
- Aug 21, 2023
Human Erythropoietin Injection
- Product Name
- 利血宝
- Approval Number
- 国药准字SJ20171016
- Approval Date
- Aug 21, 2023
Human Granulocyte Colony-stimulating Factor Injection
- Product Name
- 惠尔血
- Approval Number
- 国药准字SJ20171037
- Approval Date
- Feb 6, 2023
Human Granulocyte Colony-stimulating Factor Injection
- Product Name
- 惠尔血
- Approval Number
- 国药准字SJ20171035
- Approval Date
- Aug 10, 2022
Human Granulocyte Colony-stimulating Factor Injection
- Product Name
- 惠尔血
- Approval Number
- 国药准字SJ20171033
- Approval Date
- Aug 10, 2022
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (212 trials with phase data)• Click on a phase to view related trials
Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT06926491
- Locations
- 🇯🇵
Aichi Children's Health and Medical Center, Ōbu, Aichi, Japan
🇯🇵Osaka University Hospital, Suita, Osaka, Japan
🇯🇵Osaka Women's and Children's Hospital, Waizumi, Osaka, Japan
Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension
- Conditions
- Healthy Volunteers Essential Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT06823947
- Locations
- 🇯🇵
Kitasato University Kitasato Institute Hospital, Minato-ku, Tokyo, Japan
Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia
- Interventions
- Drug: KK2845_2Drug: KK2845_1Drug: KK2845_3Drug: KK2845_4
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06812104
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06525636
- Locations
- 🇺🇸
Yale Center for XLH/ Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸University of California - San Francisco, San Francisco, California, United States
🇺🇸Indiana University School of Medicine University Hospital, Indianapolis, Indiana, United States
A Study of KK2269 in Adult Participants With Solid Tumors
- Conditions
- Metastatic Solid TumorEsophageal AdenocarcinomaAdvanced Solid TumorGastroesophageal Junction AdenocarcinomaNon Small Cell Lung CancerGastric Adenocarcinoma
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 71
- Registration Number
- NCT06266299
- Locations
- 🇺🇸
City Of Hope, Duarte, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇯🇵Aichi Cancer Center, Nagoya city, Aichi, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 32
- Next
News
Kura Oncology Initiates Phase 1 Trial Combining Ziftomenib with Imatinib for Advanced GIST Treatment
Kura Oncology has dosed first patients in KOMET-015, a Phase 1 trial evaluating ziftomenib in combination with imatinib for advanced gastrointestinal stromal tumors (GIST) after imatinib failure.
Fasenra Approved in the EU for Eosinophilic Granulomatosis with Polyangiitis
AstraZeneca's Fasenra (benralizumab) has been approved in the EU for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).